Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin - PubMed (original) (raw)
. 2009 Apr;132(Pt 4):919-32.
doi: 10.1093/brain/awp006. Epub 2009 Feb 18.
Affiliations
- PMID: 19224899
- DOI: 10.1093/brain/awp006
Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin
Mahmoud A Pouladi et al. Brain. 2009 Apr.
Abstract
Huntington disease is a neurodegenerative disorder caused by an expanded CAG repeat in the Huntington disease gene. The symptomatic phase of the disease is defined by the onset of motor symptoms. However, psychiatric disturbances, including depression, are common features of Huntington disease and recent studies indicate that depression can occur long before the manifestation of motor symptoms. The aetiology of depression in Huntington disease is not fully understood and psychosocial factors such as the knowledge of carrying a mutation for an incurable disease or adverse social circumstances may contribute to its presentation. Due to the difficulties in discriminating between social and biological factors as contributors to depression in clinical Huntington disease, we chose to assess whether a model for Huntington disease not subject to environmental stressors, namely the YAC mouse model of Huntington disease, displays a depressive phenotype. Indeed, the YAC transgenic mice recapitulate the early depressive phenotype of Huntington disease as assessed by the Porsolt forced swim test as well as the sucrose intake test as a measure of anhedonia. The YAC model mirrors clinical Huntington disease in that there were no effects of CAG repeat length or disease duration on the depressive phenotype. The depressive phenotype was completely rescued in YAC transgenic animals expressing a variant of mutant huntingtin that is resistant to cleavage at amino acid 586 suggesting that therapies aimed towards inhibition of huntingtin cleavage are also likely to have beneficial effects on this aspect of the disease. In conclusion, our study provides strong support for a primary neurobiological basis for depression in Huntington disease.
Similar articles
- Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group; Roos RA. Aziz NA, et al. Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e. Neurology. 2008. PMID: 18981372 Clinical Trial. - Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease.
Hult Lundh S, Nilsson N, Soylu R, Kirik D, Petersén Å. Hult Lundh S, et al. Hum Mol Genet. 2013 Sep 1;22(17):3485-97. doi: 10.1093/hmg/ddt203. Epub 2013 May 22. Hum Mol Genet. 2013. PMID: 23697793 - Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.
Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, Bissada N, Franciosi S, Hayden MR. Graham RK, et al. J Huntingtons Dis. 2012;1(2):243-60. doi: 10.3233/JHD-120038. J Huntingtons Dis. 2012. PMID: 25063333 - Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM, Warby SC, Hayden MR. Van Raamsdonk JM, et al. Brain Res Bull. 2007 Apr 30;72(2-3):124-31. doi: 10.1016/j.brainresbull.2006.10.018. Epub 2006 Nov 16. Brain Res Bull. 2007. PMID: 17352936 Review. - Huntington disease: clinical, genetic, and social aspects.
Nance MA. Nance MA. J Geriatr Psychiatry Neurol. 1998 Summer;11(2):61-70. doi: 10.1177/089198879801100204. J Geriatr Psychiatry Neurol. 1998. PMID: 9877527 Review.
Cited by
- An optimized activity-based probe for the study of caspase-6 activation.
Edgington LE, van Raam BJ, Verdoes M, Wierschem C, Salvesen GS, Bogyo M. Edgington LE, et al. Chem Biol. 2012 Mar 23;19(3):340-52. doi: 10.1016/j.chembiol.2011.12.021. Chem Biol. 2012. PMID: 22444589 Free PMC article. - Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.
Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M. Switonski PM, et al. Mol Neurobiol. 2012 Oct;46(2):430-66. doi: 10.1007/s12035-012-8316-3. Epub 2012 Sep 4. Mol Neurobiol. 2012. PMID: 22944909 Free PMC article. Review. - Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Rα receptor.
Wu X, Hsuchou H, Kastin AJ, He Y, Khan RS, Stone KP, Cash MS, Pan W. Wu X, et al. Psychoneuroendocrinology. 2011 Feb;36(2):266-78. doi: 10.1016/j.psyneuen.2010.07.017. Epub 2010 Aug 17. Psychoneuroendocrinology. 2011. PMID: 20724079 Free PMC article. - Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, Misra K, Cheng SH, Shihabuddin LS. Stanek LM, et al. Hum Gene Ther. 2014 May;25(5):461-74. doi: 10.1089/hum.2013.200. Epub 2014 Mar 21. Hum Gene Ther. 2014. PMID: 24484067 Free PMC article. - Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.
Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR. Ehrnhoefer DE, et al. Acta Neuropathol Commun. 2018 Mar 6;6(1):16. doi: 10.1186/s40478-018-0518-0. Acta Neuropathol Commun. 2018. PMID: 29510748 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical